Multi-Platform Approach to Genotyping

CGI provides high quality genotyping services for clinical trials, which adhere to stringent regulatory standards including GLP, CLIA, and GCP. Our strategy is to be “platform agnostic”, meaning that CGI is not dedicated to any one technology platform. The flexibility, scalability, and versatility, provided by a multi-platform approach, allow us to provide the best solution for a wide range of client needs. CGI’s scientific team works with clients to choose the clinically relevant genes and variants, providing them with customizable, attention-driven service.

Over the past 10 years, our portfolio has grown to over 400 validated, clinical genotyping assays. If an assay for a particular gene or polymorphism is not available, CGI has extensive experience in custom assay development and validation. To learn more about our capabilities, contact us for more information.

Summary of Genotyping Services

  • Over 400 validated genotyping assays including Phase I and Phase II drug metabolizing enzymes, transporters, and receptors
  • Over 30 validated gene expression assays
  • CLIA grade testing for the FDA’s Pharmacogenomic Biomarkers in Drug Labels recommended panel
  • Detection of loss of heterozygosity
  • Detection of copy number
  • High throughput genotyping
  • Microsatellite/STR analysis
  • Microsatellite Instability
Available Genotyping Platforms

  • Taqman® Allelic Discrimination
  • Sanger Sequencing
  • Ion Torrent PGMTM
  • Sequenom Mass ARRAY
  • DNA Microarray
  • DMET® Certified
  • GeneChip Human SNP 5.0 Array
  • GeneChip Human SNP 6.0 Array
  • Cytogenetic Copy Number